Search PubMed⌕ Search

Biomedical subjects

Y Narabayashi

Publications and source records attributed to Y Narabayashi.

12 recordsLinked to original sources

A specific thrombin inhibitor (argatroban) ameliorated cerebral blood flow in the patients with acute cerebral infarction.

Argatroban, one of the arginine derivatives, has been reported to have a safe and potent antithrombin action. This compound is active in several animal models of thrombosis and also has been shown to improve general neurological symptomatology, general subjective symptomatology and general daily behavior in the patients with acute thrombosis. This was considered to reflect remarkable improvement of microcirculation. No published clinical data, however, exist on the effect of argatroban on cerebral blood flow (CBF) change during acute stroke. Three patients with acute cerebral infarction were subjected to this study. Intravenous argatroban injection (2.5 mg/hr) was continued in 48 hours. Regional CBF (rCBF) was measured before and after injection of argatroban using Xe-CT method. Argatroban increased CBF not only in the injured side hemisphere or penumbra, but also contralateral side of lesion in the patients with acute cerebral infarction.

Aged↗

Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.

Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985. The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.

Aged↗

Hypotensive effect of long-term levodopa in patients with Parkinson's disease.

To study the hypotensive effect of L-dopa in patients with Parkinson's disease on long-term L-dopa, the blood pressure (BP) was measured in 14 patients and 6 controls before 100 mg L-dopa plus decarboxylase inhibitor and for up to 180 min after dosing. Plasma monoamines and motor functions were assessed. The mean BP was reduced between 60 and 180 min after dosing in the patients, whereas such a reduction was not observed in 5 patients from whom L-dopa was withheld and in controls who showed a high ratio of plasma dopamine compared to plasma L-dopa after dosing. The L-dopa-induced reduction in BP was thought to be due to a central nervous mechanism.

Aged↗

Peripheral nerve intraneural ganglion cyst: MR findings in three cases.

We present MR findings of three cases of surgically proved intraneural ganglion cysts involving the common peroneal nerve (two patients) and ulnar nerve (one patient). The lesions were located along the course of the involved nerve and situated close to a joint. MRI demonstrated the cystic nature and extent of the lesions with clear definition of the anatomic relationship of the lesions to the surrounding structures.

Adult↗